Göttingen researchers have developed mini-antibodies that efficiently block the coronavirus SARS-CoV-2 and its dangerous new variants. These so-called nanobodies bind and neutralize the virus up to 1000 times better than previously developed mini-antibodies. In addition, the scientists optimized their mini-antibodies for stability and resistance to extreme heat. This unique combination makes them promising agents to treat COVID-19. Since nanobodies can be produced at low costs in large quantities, they could meet the global demand for COVID-19 therapeutics. The new nanobodies are currently in preparation for clinical trials.
Research team from the Kiel Evolution Center investigates the role of a reduction in bacterial population size and resulting random effects in the evolution of antibiotic resistance
A major challenge in cancer therapy is the adaptive response of cancer cells to targeted therapies. Although this adaptive response is theoretically reversible, such a reversal is hampered by numerous molecular mechanisms that allow the cancer cells to adapt to the treatment. A team has used information theory, in order to objectify in vivo the molecular regulations at play in the mechanisms of the adaptive response and their modulation by a therapeutic combination.
Pancreatic cancer cells typically rely on a mutant version of the KRAS protein to proliferate. These cancer cells can also survive losing KRAS by activating alternative growth pathways. Scientists discovered a new interaction between mutant KRAS and a protein complex called RSK1/NF1 that may be the source of this adaptive resistance.
A gene duplication leads to frogs of the genus Leptodactylus being resistant to certain poisons. This was discovered by an international research team with the participation of the Department of Biology at Universität Hamburg. The results show that the study of gene duplicates can help identify important genetic interactions.
Low doses of a four-drug combination helps prevent the spread of cancer in mice without triggering drug resistance or recurrence, shows a new study.
Early results from a new, pioneering chimeric antigen receptor (CAR) T cell immunotherapy trial found using a bilateral attack achieves a more robust defense and helps avoid relapse.
Researchers have found that blocking a specific protein could increase tumor sensitivity to treatment with PARP inhibitors. Their work suggests combining treatments could lead to improved therapy for patients with inheritable breast cancers.
Lung tumors are home to immune cells that affect their growth and resistance to treatment. Looking at neutrophils, scientists led by EPFL have discovered that the key might lie in the cells’ ability to metabolize glucose, opening an entirely new target for improving radiotherapy.
An international research team has developed a model that predicts growth rates and resistance mechanisms of common bacterial mutants at different drug doses / Publication in ‘Nature Ecology & Evolution’
The use of antimicrobial drugs and the subsequent selection for antibiotic-resistant bacteria is a global health problem affecting humans, animals and the environment. A research team from Vetmeduni Vienna has examined a possible factor influencing this problem in more detail, namely the feeding of waste milk – milk that does not meet the legal requirements for human consumption – to calves. The researchers argue that more attention should be paid to the possible negative consequences of this feeding practice and that alternative strategies must be explored.
Scientists have created an advanced humanized immune system mouse model that allows them to examine resistance to immune checkpoint blockade therapies in melanoma. It has revealed a central role for mast cells.
Scientists have discovered a new class of compounds that uniquely combine direct antibiotic killing of pan drug-resistant bacterial pathogens with a simultaneous rapid immune response for combating antimicrobial resistance (AMR).
Antibiotics have revolutionized medicine by providing effective treatments for infectious diseases such as cholera. But the pathogens that cause disease are increasingly developing resistance to the antibiotics that are most commonly used. Scientists at the Friedrich Schiller University Jena, Germany have discovered a molecule that influences the antibiotic-resistance of cholera bacteria. They have published their results in the scientific journal “Nature Communications”.
Age may cause identical cancer cells with the same mutations to behave differently. In animal and laboratory models of melanoma cells, age was a primary factor in treatment response.
Multidrug resistance (MDR) — a process in which tumors become resistant to multiple medicines — is the main cause of failure of cancer chemotherapy. Tumor cells often acquire MDR by boosting their production of proteins that pump drugs out of the cell, rendering the chemotherapies ineffective. Now, researchers have developed nanoparticles that release bursts of calcium inside tumor cells, inhibiting drug pumps and reversing MDR.
Drugs tackling chronic myelogenous leukemia have completely transformed prognoses of patients over the last couple of decades, with most cases going into remission. But drug resistance can occur, leading to relapses. Targeting the lipids involved in regulating part of a leukemia stem cell’s life span offers a potential second route to defeat the disease — and solid tumorous cancers as well.
Researchers from CeMM Research Center of Molecular Medicine of the Austrian Academy of Sciences, the Medical University of Vienna and Stanford University School of Medicine, have found that a module of the immune system, which is best known for causing allergic reactions, plays a key role in acquiring host defense against infections triggered by the bacterium Staphylococcus aureus. This “allergy module”, constituted by mast cells and Immunoglobulin E, can grant protection and increased resistance against secondary bacterial infections in the body. These findings indicate a beneficial function for allergic immune responses and are now published in the renowned journal Immunity.
Researchers say it can take cells in different forms or ‘life stages’ to cause cancer to grow and spread.
Leap forward in the fight against antibiotic resistance
Research team from Kiel University investigates how the application of antibiotics affects the mechanisms of plasmid-mediated inheritance of resistance genes
Researchers have discovered a new method to treat human herpes viruses. The new broad-spectrum method targets physical properties in the genome of the virus rather than viral proteins, which have previously been targeted. The treatment consists of new molecules that penetrate the protein shell of the virus and prevent genes from leaving the virus to infect the cell. It does not lead to resistance and acts independently of mutations in the genome of the virus.
One of the largest problems with cancer treatment is the development of resistance to anticancer therapies. A research team found that repurposing a commonly used chemotherapy drug using a nanoparticle was more effective than both a solution of the pure drug and other available treatments.
Resistance of cancer cells against therapeutic agents is a major cause of treatment failure, especially in recurrent diseases. An international team has now identified a novel mechanism of chemoresistance.
Drug resistance is a major obstacle in cancer treatment — leading to relapse for many patients. In a new study, researchers report on a promising new strategy to overcome drug resistance in leukemia, using targeted doses of the widely-used chemotherapy drug doxorubicin.